Lars Rebien Sørensen, the the outgoing CEO of Danish pharma giant Novo Nordisk (NVO), the world’s largest insulin maker, claimed HBR’s number one spot for 2016. Sørensen and his fellow CEOs were judged on a variety of financial, environmental, social, and governance metrics.
Martin Sorrell of British PR giant WPP and Pablo Isla of Spanish clothing retailer Inditex took the number 2 and 3 spots, respectively.
Subscribe to Brainstorm Health Daily, our upcoming newsletter about health innovations.
There were 10 other biopharma and health care chiefs in the top 100 CEOs list other than Sørensen, including outgoing Biogen head honcho George Scangos and Larry Merlo of CVS Health:
- Michael Mussallem, Edwards Lifesciences (EW), #20
- George Scangos, Biogen (BIIB), #21
- Lars Rasmussen, Coloplast, #24
- Jean-Paul Clozel, Actelion (ALIOF), #59
- Larry Merlo, CVS Health (CVS), #60
- Leonard Schleifer, Regeneron (REGN), #67
- Kent Thiry, DaVita (DVA), #82
- Haruo Naito, Eisai, #87
- Christopher Rex, Ramsay Health Care, #88
- Neal Patterson, Cerner (CERN), #90
So why did Sørensen earn the top prize? Mostly, for his role overseeing astonishing returns for shareholders and market capitalization growth. (An average of country-adjusted total shareholder return, industry-adjusted total shareholder return, and change in market capitalization over the course of the CEOs’ tenures accounted for 80% of the rankings’ relative weightings.)
But HBR has also recently begun incorporating environmental, social, and governance (ESG) rankings into their methodology in order to highlight corporate leaders who think beyond just short-term gains and dollars and cents. These admittedly more subjective judgments, which accounted for 20% of HBR’s weighting, boosted Sørensen, who ranked sixth on the list when judged purely by financial metrics, to the number one spot.
But as the authors note, even the world’s top CEOs aren’t immune from the chaos of a shifting business environment. Novo announced in September that Sørensen will be stepping down early after 16 years at the helm in the face of intense drug pricing scrutiny in the U.S., which has ravaged Novo’s share price since its December 2015 peak.
Sørensen doesn’t seem too concerned about his long-term legacy, though.
“My influence, through collaboration with my management team, will be assessed in 15 or 20 years, and only then will people be able to determine whether we made the right choices,” he told HBR.